COgnitioN With VERiciGuat Evaluation in Heart Failure
Launched by UNIVERSITY OF ALBERTA · Sep 13, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The COgnitioN With VERiciGuat Evaluation in Heart Failure trial, also known as CONVERGE-HF, is a research study looking at how a medication called vericiguat may help patients with chronic heart failure who also have mild to moderate cognitive impairment, which means they might have some trouble with memory or thinking. This study will take place at four medical centers and is designed for adults aged 65 to 74 years who have been living with heart failure for at least six months.
To participate, individuals must have a confirmed diagnosis of chronic heart failure and meet specific criteria for cognitive impairment, as assessed by a simple test called the Montreal Cognitive Assessment (MoCA). However, certain patients won't be eligible, such as those who have specific health issues, are currently hospitalized, or have allergies to the study medication. If you qualify and decide to join, you can expect to receive close medical supervision and participate in assessments to help researchers learn more about how vericiguat affects heart function and cognitive abilities in people like you. This trial is not yet recruiting, so it’s important to keep an eye out for updates if you or someone you know might be interested.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult patients
- • 2. Established chronic heart failure (≥ 6 months)
- • 3. Mild-to-moderate cognitive impairment (as per the diagnosis of cognitive impairment or a Montreal Cognitive Assessment (MoCA) score 10-25).
- Exclusion Criteria:
- • 1. Patients who have contraindications for sGC stimulator and vericiguat therapy (i.e. use of long-acting nitrates, other soluble guanylate cyclase stimulators (e.g., riociguat), or phosphodiesterase type 5 (PDE-5), pregnancy or breast-feeding)
- • 2. Unable to undergo CMR imaging or brain MRI.
- • 3. CMR exclusions: renal failure \[a glomerular filtration rate \<30 mL/min)\], incompatible implantable cardiac device (ICD or CRT), uncontrolled atrial fibrillation or recurrent ventricular arrhythmias).
- • 4. General medical conditions: uncontrolled thyroid disorders, hepatic failure, or myocardial revascularization procedures \[coronary angioplasty and/or surgical revascularization in the previous 3 months\], cancer/malignancy, or with severe dementia).
- • 5. Patients with allergies to the study products.
- • 6. Patients currently hospitalized.
About University Of Alberta
The University of Alberta, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong commitment to scientific excellence and community health, the university facilitates cutting-edge research across various medical disciplines. Its interdisciplinary approach fosters collaboration among researchers, clinicians, and students, ensuring that clinical trials are designed and conducted with the utmost rigor and ethical standards. By leveraging its extensive resources and expertise, the University of Alberta aims to translate research findings into meaningful advancements in patient care and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Calgary, Alberta, Canada
Ottawa, Ontario, Canada
Montreal, Quebec, Canada
Patients applied
Trial Officials
Justin Ezekowitz, MBBCh, MSc
Principal Investigator
University of Alberta
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported